X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ORCHID PHARMA LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ORCHID PHARMA LTD DIVIS LABORATORIES/
ORCHID PHARMA LTD
 
P/E (TTM) x 18.8 -0.8 - View Chart
P/BV x 4.1 0.6 720.2% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 DIVIS LABORATORIES   ORCHID PHARMA LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
ORCHID PHARMA LTD
Sep-13
DIVIS LABORATORIES/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs2,484194 1,280.2%   
Low Rs91835 2,623.1%   
Sales per share (Unadj.) Rs142.3276.5 51.5%  
Earnings per share (Unadj.) Rs41.9-79.2 -52.9%  
Cash flow per share (Unadj.) Rs46.3-43.5 -106.6%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs161.553.9 299.4%  
Shares outstanding (eoy) m265.4770.45 376.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x12.00.4 2,887.0%   
Avg P/E ratio x40.6-1.4 -2,809.4%  
P/CF ratio (eoy) x36.7-2.6 -1,393.0%  
Price / Book Value ratio x10.52.1 496.1%  
Dividend payout %23.90-   
Avg Mkt Cap Rs m451,5258,067 5,597.5%   
No. of employees `0003.72.8 132.4%   
Total wages/salary Rs m3,6492,527 144.4%   
Avg. sales/employee Rs Th10,184.46,956.1 146.4%   
Avg. wages/employee Rs Th984.1902.5 109.0%   
Avg. net profit/employee Rs Th2,998.5-1,993.0 -150.5%   
INCOME DATA
Net Sales Rs m37,76419,477 193.9%  
Other income Rs m848407 208.3%   
Total revenues Rs m38,61219,884 194.2%   
Gross profit Rs m14,1381,103 1,282.2%  
Depreciation Rs m1,1822,519 46.9%   
Interest Rs m235,227 0.4%   
Profit before tax Rs m13,781-6,236 -221.0%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m2,662-125 -2,126.5%   
Profit after tax Rs m11,119-5,580 -199.2%  
Gross profit margin %37.45.7 661.3%  
Effective tax rate %19.32.0 962.3%   
Net profit margin %29.4-28.7 -102.8%  
BALANCE SHEET DATA
Current assets Rs m30,94711,014 281.0%   
Current liabilities Rs m5,19532,060 16.2%   
Net working cap to sales %68.2-108.1 -63.1%  
Current ratio x6.00.3 1,734.0%  
Inventory Days Days11795 123.1%  
Debtors Days Days8534 253.7%  
Net fixed assets Rs m17,02729,440 57.8%   
Share capital Rs m531705 75.4%   
"Free" reserves Rs m42,3412,043 2,072.9%   
Net worth Rs m42,8773,800 1,128.4%   
Long term debt Rs m59,018 0.1%   
Total assets Rs m49,68446,510 106.8%  
Interest coverage x595.0-0.2 -308,100.7%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.80.4 181.5%   
Return on assets %22.4-0.8 -2,950.5%  
Return on equity %25.9-146.9 -17.7%  
Return on capital %32.2-3.7 -862.0%  
Exports to sales %85.337.9 225.1%   
Imports to sales %22.922.6 101.3%   
Exports (fob) Rs m32,1987,378 436.4%   
Imports (cif) Rs m8,6544,406 196.4%   
Fx inflow Rs m32,2707,513 429.5%   
Fx outflow Rs m8,7755,649 155.3%   
Net fx Rs m23,4961,865 1,260.2%   
CASH FLOW
From Operations Rs m10,3791,682 617.2%  
From Investments Rs m-4,135-9,860 41.9%  
From Financial Activity Rs m-6,2416,644 -93.9%  
Net Cashflow Rs m3-1,535 -0.2%  

Share Holding

Indian Promoters % 52.0 32.3 161.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 4.6 256.5%  
FIIs % 19.0 3.3 575.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.2 55.3 31.1%  
Shareholders   31,796 84,811 37.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 16, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS